Company: WHWK
Filing Date: 2025-01-31
Form Type: DEFM14A
Source: 0001193125-25-018470
Chunk: 161

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-31
Form: DEFM14A
Chunk 161
---
 significantly delayed. Following discussion, the PIPE Pricing Committee directed Aadi’s management team to continue to negotiate the best possible price in the PIPE Financing. The PIPE
Pricing Committee also expressed support for the proposed parameters for the PIPE Financing relating to size and price as presented.

On that same day,
Aadi’s board of directors held a virtual meeting at which representatives of Aadi’s management team, Leerink Partners and Wilson Sonsini were present. At the meeting, Aadi’s management team presented regarding the status of the
License Agreement, which was in substantially final form, and also the PIPE Financing, including the updated investor list presented to the PIPE Pricing Committee, proposed allocations, and proposed parameters for the PIPE Financing relating to size
and price. The PIPE Pricing Committee also reported to Aadi’s board of directors regarding the matters discussed at the meeting of the committee earlier that day. The PIPE Pricing Committee noted that it was supportive of the proposed
parameters for the PIPE Financing relating to size and price as presented to the PIPE Pricing Committee and Aadi’s board of directors. Following discussion, Aadi’s board of directors unanimously delegated to Dr. Lennon and Scott
Giacobello, Aadi’s Chief Financial Officer, the authority to sell and issue an amount of Aadi’s common stock and/or pre-funded warrants pursuant to the terms of the Subscription Agreement presented
to Aadi’s board of directors, which was in substantially final form, provided that the price per share would be no less than the lower of (i) the closing price of Aadi’s common stock on the Nasdaq Capital Market on December 19,
2024, and (ii) the five-day average closing price of Aadi’s common stock on the Nasdaq Capital Market ending on December 19, 2024 and that such issuance would occur on the timing contemplated in
the Subscription Agreement, so long as either of such officers executed the Subscription Agreement by no later than December 20, 2024, and that no more than $110 million worth of shares and/or
pre-funded warrants would be issued pursuant to such terms. Aadi’s board of directors further unanimously approved the License Agreement and the PIPE Financing and related matters, including the forms of
Subscription Agreement, Registration Rights Agreement and Pre-Funded Warrant. At the

- 107 -

meeting, Aadi’s board of directors also unanimously appointed Dr. Baiteng Zhao to Aadi’s board of directors. Dr. Zhao has significant expertise in the preclinical and clinical development of ADC drug conjugates